Alemtuzumab and febrile neutropenia Patient Reports February 13, 2012

Alemtuzumab Side Effects Report #6119032-0
Alemtuzumab side effect was reported by a Physician from GERMANY on Mar 10, 2009. Female patient, 64 years of age, was diagnosed with t-cell lymphoma, antifungal prophylaxis and was treated with Alemtuzumab. After drug was administered, patient experienced the following side effects: febrile neutropenia, haematochezia, haematuria. Alemtuzumab dosage: unknown. During the same period patient was treated with PREDNISONE, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PEGFILGRASTIM, LENOGRASTIM, TRIMETHOPRIM. Patient was hospitalized. Patient recovered.

Alemtuzumab Side Effects Report #5694796-9
Alemtuzumab side effect was reported by a Health Professional from UNITED STATES on Mar 20, 2008. Male patient, 55 years of age, was diagnosed with chronic lymphocytic leukaemia, enterococcal infection, klebsiella infection and was treated with Alemtuzumab. After drug was administered, patient experienced the following side effects: bacterial infection , bronchopulmonary aspergillosis, febrile neutropenia, pancytopenia. Alemtuzumab dosage: unknown. During the same period patient was treated with QUINUPRISTIN, MEROPENEM. Patient was hospitalized. Patient died.

Alemtuzumab Side Effects Report #5695685-6
Alemtuzumab side effect was reported by a Health Professional from UNITED STATES on Mar 20, 2008. Male patient, 55 years of age, was diagnosed with chronic lymphocytic leukaemia, enterococcal infection, klebsiella infection and was treated with Alemtuzumab. After drug was administered, patient experienced the following side effects: bacterial infection , bronchopulmonary aspergillosis, febrile neutropenia, pancytopenia. Alemtuzumab dosage: unknown. During the same period patient was treated with QUINUPRISTIN, MEROPENEM. Patient was hospitalized. Patient died.

Alemtuzumab Side Effects Report #5545993-4
Alemtuzumab side effect was reported by a Health Professional from UNITED KINGDOM on Nov 26, 2007. Male patient, 25 years of age, was diagnosed with bone marrow conditioning regimen, immunosuppression, lymphoproliferative disorder and was treated with Alemtuzumab. After drug was administered, patient experienced the following side effects: alveolitis fibrosing, anaemia, ascites, cryptogenic organising pneumonia, febrile neutropenia, gastrointestinal haemorrhage, hepatic cirrhosis, melaena. Alemtuzumab dosage: unknown. During the same period patient was treated with FLUDARABINE PHOSPHATE, MELPHALAN, CYCLOSPORINE, RITUXIMAB. Patient died.


Alemtuzumab Side Effects Report #5584090-9
Alemtuzumab side effect was reported by a Health Professional from UNITED KINGDOM on Nov 26, 2007. Male patient, 25 years of age, was diagnosed with bone marrow conditioning regimen, immunosuppression, lymphoproliferative disorder and was treated with Alemtuzumab. After drug was administered, patient experienced the following side effects: alveolitis fibrosing, anaemia, ascites, cryptogenic organising pneumonia, febrile neutropenia, gastrointestinal haemorrhage, hepatic cirrhosis, melaena. Alemtuzumab dosage: unknown. During the same period patient was treated with FLUDARABINE, MELPHALAN, CYCLOSPORINE, RITUXIMAB. Patient died.

Alemtuzumab Side Effects Report #5805486-3
Alemtuzumab side effect was reported by a Consumer or non-health professional from NETHERLANDS on June 20, 2008. Male patient, 41 years of age, was diagnosed with infection prophylaxis, antiviral prophylaxis, antifungal prophylaxis and was treated with Alemtuzumab. After drug was administered, patient experienced the following side effects: cytomegalovirus infection , epstein-barr virus infection, erosive duodenitis, febrile neutropenia, histiocytosis haematophagic, lymphoproliferative disorder, t-cell lymphoma. Alemtuzumab dosage: unknown. During the same period patient was treated with PREDNISONE, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, COTRIM, VALACYCLOVIR, FLUCONAZOLE. Patient died on 07/01/2007.

Alemtuzumab Side Effects Report #5474809-X
Alemtuzumab side effect was reported by a Physician from UNITED STATES on Sept 27, 2007. Female patient, weighting 97.00 lb, was treated with Alemtuzumab. After drug was administered, patient experienced the following side effects: blood triglycerides increased, chondrocalcinosis pyrophosphate, diffuse alveolar damage, encephalitis , febrile neutropenia, histiocytosis haematophagic, hypotension, intra-abdominal haemorrhage. Alemtuzumab dosage: 30MG EVERY 3 WEEKS IV DRIP. During the same period patient was treated with ETOPOSIDE, ONCOVIN, HYDROXYLDAUNORUBICIN, CYCLOPHOSPHAMIDE, PREDNISONE, NEUPOGEN, PENTAMIDINE ISETHIONATE, ACYCLOVIR. Patient died on 05/10/2007.